Pramlintide
Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca). Pramlintide is sold as an acetate salt.
Golden line indicates disulfide bond | |
Clinical data | |
---|---|
Trade names | Symlin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605031 |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 30 to 40% |
Protein binding | ~60% |
Metabolism | Renal |
Elimination half-life | ~48 minutes |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C171H267N51O53S2 |
Molar mass | 3949.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.